NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit. Investors have until July 28, 2025, to ask the Court ...

诉讼背景 - 律师事务所Levi & Korsinsky代表投资者对UroGen Pharma Ltd提起集体诉讼 该诉讼针对2023年7月27日至2025年5月15日期间因涉嫌证券欺诈遭受损失的投资者 [1] - 投资者需在2025年7月28日前申请作为首席原告 但参与赔偿无需承担任何费用 [3] 指控内容 - 公司被指控在ENVISION临床研究设计中未设置并行对照组 导致无法有效证明其主要管线产品UGN-102的疗效归因性 [2] - 公司未能采纳FDA关于UGN-102药物申请研究设计的警告 导致新药申请（NDA）存在重大不予批准风险 [2] - 被告就公司业务运营及前景发表的积极声明因上述问题存在实质性误导或缺乏合理依据 [2] 律所资质 - Levi & Korsinsky过去20年为受损股东追回数亿美元资金 拥有70人以上专业团队 [4] - 该律所连续七年被ISS证券集体诉讼服务评为美国前50大证券诉讼律师事务所之一 [4]

NEW YORK, June 5, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of UroGen Pharma Ltd. (NASDAQ: URGN) between July 27, 2023 and May 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 28, 2025.So What: If you purchased UroGen securities during the Class Period you ma ...

SAN FRANCISCO, June 5, 2025 /PRNewswire/ -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025.The lawsuit comes after investors saw the price of their shares in UroGen Pharma Ltd. (NASDAQ: URGN) crash on May 16, 2025 as a result of the FDA's publication of a briefing document a few days before an upcoming Oncolo ...

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in UroGen Pharma Ltd. ("UroGen Pharma Ltd." or the "Company") (NASDAQ: URGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of UroGen Pharma Ltd. investors who were adversely affected by alleged securities fraud between July 27, 2023 and May 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/urogen-p ...

文章核心观点 - 针对UroGen Pharma Ltd 的证券集体诉讼已提起 指控公司在2023年7月27日至2025年5月15日期间就其主要候选药物UGN-102的临床试验设计和监管前景做出重大虚假和误导性陈述 [1][2] 诉讼相关方及时间范围 - 诉讼由Wolf Haldenstein Adler Freeman & Herz LLP律所代表在2023年7月27日至2025年5月15日期间购买或收购UroGen Pharma Ltd 证券的个人或实体提起 [1] - 主要原告动议的截止日期为2025年7月28日 [5] 关键事件与市场反应 - 2025年5月16日 美国FDA发布简报文件 对UGN-102提交数据的充分性表示担忧 特别批评其缺乏随机对照试验 导致公司股价下跌25.8% 收于每股7.31美元 [3] - 2025年5月21日 FDA肿瘤药物咨询委员会投票反对批准UGN-102 理由是获益风险特征不佳 导致公司股价进一步下跌44.7% 收于每股4.17美元 [3][4]

NEW YORK, June 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. (NASDAQ: URGN). Shareholders who purchased shares of URGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rig ...

SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025. The lawsuit comes after investors saw the price of their shares in UroGen Pharma Ltd. (NASDAQ: URGN) crash on May 16, 2025 as a result of the FDA’s publication of a briefing document a few days before an upcoming ...

LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 28, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR UROGEN INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In UroGen To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in UroGen between July 27, 2023 and May 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 /PRNewswire/ -- Faru ...